Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244439 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice
A Phase 3 study of Lice Infestations, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 6
- Study locations
NCT00244439: Completed Phase 3 study of Lice Infestations, sponsored by Sun Pharmaceutical Industries.
NCT00244439 is a Phase 3 study of Lice Infestations that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 360 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244439, a Phase 3 study of Lice Infestations, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 6
- Study locations
Study Summary
Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.
Conditions Studied
Interventions
- DRUG MALG
- DRUG Ovide (malathion) lotion 0.05%
- DRUG Permethrin 1%
Study Locations (6)
Florida
- Investigator Site - Miami
- Investigator Site - St. Petersburg
- Investigator Site - West Palm Beach
Arizona
- Investigator Site - Scottsdale
New York
- Investigator Site - New York
Ohio
- Investigator Site - Miamiville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
What the finished NCT00244439 record still lists
NCT00244439 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Lice Infestations appearing as the primary indexed condition, and to 3 interventions - of which MALG is the first listed.
NCT00244439 lists 6 locations in 4 states (Florida, Arizona, New York).
Frequently Asked Questions
What is clinical trial NCT00244439 about?
NCT00244439 is a clinical study titled "Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice". Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will ...
What is the current status of trial NCT00244439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2005-12. Estimated completion is 2006-12.
What conditions does trial NCT00244439 study?
This clinical trial studies the following conditions: Lice Infestations.
What interventions are being tested in trial NCT00244439?
The interventions under investigation include: MALG (DRUG), Ovide (malathion) lotion 0.05% (DRUG), Permethrin 1% (DRUG).
Who is sponsoring clinical trial NCT00244439?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00244439 being conducted?
This trial has 6 study locations across Arizona, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00244439's enrollment target sits among peer trials
360 1008th of 2000 higher than 980 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia